Pediatric Cancer Treatment Drugs Market Share

APAC Market Statistics

Regionally, the global pediatric cancer treatment drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is poised to dominate majority revenue share by 2036, ascribed to increasing government investments to enhance the medical infrastructure, and rising awareness about different treatment options in pediatric oncology. As per the World Bank, the health expenditure of China stood at 5.351% of the total GDP in the year 2018, up from 5.151% and 4.982% in 2017 and 2016 respectively.

North America Market Analysis

Moreover, the market in North America is expected to occupy the largest share during the forecast period owing to the favorable reimbursement from public and private health insurance firms in the region. In addition, increase in the number of research partnerships among companies is also projected to drive market growth in the region in the coming years.

Frequently Asked Questions (FAQ)

Pediatric Cancer Treatment Drugs Market size is poised to witness lucrative growth rate during the forecast period i.e., between 2024-2036.

The market growth is driven by increasing occurrence of cancer among children, and rising prevalence of childhood obesity worldwide.

Asia Pacific industry is poised to dominate majority revenue share by 2036, ascribed to increasing government investments to enhance the medical infrastructure, and rising awareness about different treatment options in pediatric oncology.

The major players in the market are Bristol Myers Squibb Company, Epizyme, Inc., Eisai Co., Ltd., Recordati Rare Diseases Inc., Merck & Co., Inc., and others.

Pediatric Cancer Treatment Drugs Market Share